Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 34, pp. 4194 - 4201
Comparative effectiveness research (CER) has been promoted as a way to improve the translation gap between clinical research and everyday clinical practice as...
IRRADIATION | POSITRON-EMISSION-TOMOGRAPHY | CHEMOTHERAPY REGIMENS | ONCOLOGY | RALOXIFENE | TAMOXIFEN | BREAST-CANCER CHEMOPREVENTION | CLINICAL-TRIALS | LUMPECTOMY | OUTCOMES | AXILLARY DISSECTION | Comparative Effectiveness Research - methods | Randomized Controlled Trials as Topic - methods | Humans | Comparative Effectiveness Research - trends | Randomized Controlled Trials as Topic - standards
IRRADIATION | POSITRON-EMISSION-TOMOGRAPHY | CHEMOTHERAPY REGIMENS | ONCOLOGY | RALOXIFENE | TAMOXIFEN | BREAST-CANCER CHEMOPREVENTION | CLINICAL-TRIALS | LUMPECTOMY | OUTCOMES | AXILLARY DISSECTION | Comparative Effectiveness Research - methods | Randomized Controlled Trials as Topic - methods | Humans | Comparative Effectiveness Research - trends | Randomized Controlled Trials as Topic - standards
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2008, Volume 26, Issue 28, pp. 4572 - 4578
Purpose Sorafenib is an antiangiogenic agent with activity in renal cancer. We conducted a randomized trial to investigate dynamic contrast magnetic resonance...
LIVER METASTASES | FACTOR RECEPTOR INHIBITOR | ORAL ANGIOGENESIS INHIBITOR | BAY-43-9006 | ONCOLOGY | MRI | RAF KINASE | REFRACTORY SOLID TUMORS | PHASE-I | CANCER | CELL CARCINOMA | Niacinamide - analogs & derivatives | Prospective Studies | Area Under Curve | Humans | Middle Aged | Magnetic Resonance Imaging - methods | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - pharmacokinetics | Aged, 80 and over | Placebos | Adult | Female | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Biomarkers, Tumor - analysis | Carcinoma, Renal Cell - pathology | Proportional Hazards Models | Treatment Outcome | Contrast Media | Survival Analysis | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Gadolinium DTPA | Genitourinary Cancer
LIVER METASTASES | FACTOR RECEPTOR INHIBITOR | ORAL ANGIOGENESIS INHIBITOR | BAY-43-9006 | ONCOLOGY | MRI | RAF KINASE | REFRACTORY SOLID TUMORS | PHASE-I | CANCER | CELL CARCINOMA | Niacinamide - analogs & derivatives | Prospective Studies | Area Under Curve | Humans | Middle Aged | Magnetic Resonance Imaging - methods | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - pharmacokinetics | Aged, 80 and over | Placebos | Adult | Female | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Biomarkers, Tumor - analysis | Carcinoma, Renal Cell - pathology | Proportional Hazards Models | Treatment Outcome | Contrast Media | Survival Analysis | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Gadolinium DTPA | Genitourinary Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6, pp. 591 - 597
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for...
SURVIVAL | IMPACT | EVEROLIMUS | PAZOPANIB | ONCOLOGY | VEGF | KINASE | GROWTH | BONE | INHIBITOR | MET | Pyridines - administration & dosage | Drug Administration Schedule | Carcinoma, Renal Cell - pathology | Humans | Middle Aged | Risk Factors | Male | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Indoles - administration & dosage | Disease-Free Survival | Neoplasm Metastasis | Sunitinib | Anilides - administration & dosage | Pyrroles - administration & dosage | Aged, 80 and over | Adult | Female | Kidney Neoplasms - pathology | Aged | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | ORIGINAL REPORTS
SURVIVAL | IMPACT | EVEROLIMUS | PAZOPANIB | ONCOLOGY | VEGF | KINASE | GROWTH | BONE | INHIBITOR | MET | Pyridines - administration & dosage | Drug Administration Schedule | Carcinoma, Renal Cell - pathology | Humans | Middle Aged | Risk Factors | Male | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Indoles - administration & dosage | Disease-Free Survival | Neoplasm Metastasis | Sunitinib | Anilides - administration & dosage | Pyrroles - administration & dosage | Aged, 80 and over | Adult | Female | Kidney Neoplasms - pathology | Aged | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 1, pp. 13 - 21
Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy...
TRIAL | SURVIVAL | THERAPY | CISPLATIN | ONCOLOGY | SUBTYPES | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - chemically induced | Triple Negative Breast Neoplasms - drug therapy | Cyclophosphamide - adverse effects | Bevacizumab | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Hypertension - chemically induced | Adult | Female | Neoadjuvant Therapy | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Thrombocytopenia - chemically induced | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Bc5 | ORIGINAL REPORTS
TRIAL | SURVIVAL | THERAPY | CISPLATIN | ONCOLOGY | SUBTYPES | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Fatigue - chemically induced | Triple Negative Breast Neoplasms - drug therapy | Cyclophosphamide - adverse effects | Bevacizumab | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Hypertension - chemically induced | Adult | Female | Neoadjuvant Therapy | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Thrombocytopenia - chemically induced | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Bc5 | ORIGINAL REPORTS
Journal Article
BJU International, ISSN 1464-4096, 04/2018, Volume 121, Issue 4, pp. 534 - 539
Objective To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. Methods The Men's Eating...
carotenoids | outcomes | PCSM | ProstateCancer | diet | prevention | active surveillance | DIAGNOSIS | CELLS | MANAGEMENT | LIFE-STYLE CHANGES | FOLLOW-UP | RISK | UROLOGY & NEPHROLOGY | COHORT | PROGRESSION | Prostatic Neoplasms - pathology | Vegetables | Diet - statistics & numerical data | Humans | Middle Aged | Male | Prostatic Neoplasms - diet therapy | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - epidemiology | Biopsy | Aged, 80 and over | Aged | Prostatic Neoplasms - prevention & control | Diet - methods | Prevention | Medical research | Carotenoids | Analysis | Clinical trials | Medicine, Experimental | Prostate cancer | Demography | Diet | Surveillance | Feasibility studies | Prostate | Minority & ethnic groups
carotenoids | outcomes | PCSM | ProstateCancer | diet | prevention | active surveillance | DIAGNOSIS | CELLS | MANAGEMENT | LIFE-STYLE CHANGES | FOLLOW-UP | RISK | UROLOGY & NEPHROLOGY | COHORT | PROGRESSION | Prostatic Neoplasms - pathology | Vegetables | Diet - statistics & numerical data | Humans | Middle Aged | Male | Prostatic Neoplasms - diet therapy | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - epidemiology | Biopsy | Aged, 80 and over | Aged | Prostatic Neoplasms - prevention & control | Diet - methods | Prevention | Medical research | Carotenoids | Analysis | Clinical trials | Medicine, Experimental | Prostate cancer | Demography | Diet | Surveillance | Feasibility studies | Prostate | Minority & ethnic groups
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 94, pp. 115 - 125
The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor...
IMDC risk groups | First-line | Cabozantinib | Sunitinib | Advanced renal cell carcinoma | TARGETED THERAPY | INTERFERON-ALPHA | EVEROLIMUS | PAZOPANIB | ONCOLOGY | MET | PROGNOSTIC MODEL | Antimitotic agents | Care and treatment | Patient outcomes | Clinical trials | Carcinoma, Renal cell | Metastasis | Antineoplastic agents
IMDC risk groups | First-line | Cabozantinib | Sunitinib | Advanced renal cell carcinoma | TARGETED THERAPY | INTERFERON-ALPHA | EVEROLIMUS | PAZOPANIB | ONCOLOGY | MET | PROGNOSTIC MODEL | Antimitotic agents | Care and treatment | Patient outcomes | Clinical trials | Carcinoma, Renal cell | Metastasis | Antineoplastic agents
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 9/2018, Volume 171, Issue 2, pp. 325 - 334
In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole....
Oncology | Breast cancer | Medicine & Public Health | Toxicity | Risk factors | Bevacizumab | ADJUVANT CHEMOTHERAPY | PERFORMANCE STATUS | GERIATRIC ASSESSMENT | PROGNOSTIC-FACTORS | COGNITIVE IMPAIRMENT | METASTATIC COLORECTAL-CANCER | CELL LUNG-CANCER | OLDER PATIENTS | ONCOLOGY | SOCIAL SUPPORT | COOPERATIVE-ONCOLOGY-GROUP | Letrozole - administration & dosage | Receptors, Estrogen - metabolism | Bevacizumab - administration & dosage | Humans | Middle Aged | Risk Factors | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Incidence | Receptors, Progesterone - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged, 80 and over | Female | Aged | Odds Ratio | Hypertension | Antimitotic agents | Activities of daily living | Comorbidity | Oncology, Experimental | Cognition | Research | Hormones | Antineoplastic agents | Cancer | Index Medicus | Breast Cancer
Oncology | Breast cancer | Medicine & Public Health | Toxicity | Risk factors | Bevacizumab | ADJUVANT CHEMOTHERAPY | PERFORMANCE STATUS | GERIATRIC ASSESSMENT | PROGNOSTIC-FACTORS | COGNITIVE IMPAIRMENT | METASTATIC COLORECTAL-CANCER | CELL LUNG-CANCER | OLDER PATIENTS | ONCOLOGY | SOCIAL SUPPORT | COOPERATIVE-ONCOLOGY-GROUP | Letrozole - administration & dosage | Receptors, Estrogen - metabolism | Bevacizumab - administration & dosage | Humans | Middle Aged | Risk Factors | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Incidence | Receptors, Progesterone - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged, 80 and over | Female | Aged | Odds Ratio | Hypertension | Antimitotic agents | Activities of daily living | Comorbidity | Oncology, Experimental | Cognition | Research | Hormones | Antineoplastic agents | Cancer | Index Medicus | Breast Cancer
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 11/2006, Volume 18, Issue 6, pp. 615 - 621
PURPOSE OF REVIEWSorafenib is an oral, multikinase inhibitor that was recently approved for use in metastatic renal cancer. It is currently undergoing...
Renal cell cancer | Angiogenesis | Vascular endothelial growth factor | Sorafenib | Tyrosine kinase inhibitors | tyrosine kinase inhibitors | renal cell cancer | sorafenib | ONCOLOGY | angiogenesis | vascular endothelial growth factor | Niacinamide - analogs & derivatives | Humans | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Clinical Trials as Topic | Phenylurea Compounds | Kidney Neoplasms - drug therapy | Pyridines - therapeutic use
Renal cell cancer | Angiogenesis | Vascular endothelial growth factor | Sorafenib | Tyrosine kinase inhibitors | tyrosine kinase inhibitors | renal cell cancer | sorafenib | ONCOLOGY | angiogenesis | vascular endothelial growth factor | Niacinamide - analogs & derivatives | Humans | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Clinical Trials as Topic | Phenylurea Compounds | Kidney Neoplasms - drug therapy | Pyridines - therapeutic use
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 5_suppl, pp. 17 - 17
17 Background: Advancing the quality of cancer care requires that physicians be trained in survivorship care. An oncology seminar series was designed and...
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2012, Volume 136, Issue 2, pp. 355 - 363
Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin...
Treatment | Medicine & Public Health | PIK3CA | PTEN | Oncology | Temsirolimus | Rapamycin | Breast cancer | CELLS | PTEN LOSS | PIK3CA MUTATIONS | ENHANCED SENSITIVITY | EVEROLIMUS | MTOR | ONCOLOGY | PRECLINICAL MODELS | SIGNALING PATHWAY | RESISTANCE | INHIBITOR | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Neoplasm Metastasis | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Female | Mutation | Immunohistochemistry | Antimitotic agents | Cancer patients | Analysis | Estrogen | Clinical trials | Product development | Metastasis | Antineoplastic agents | Formaldehyde
Treatment | Medicine & Public Health | PIK3CA | PTEN | Oncology | Temsirolimus | Rapamycin | Breast cancer | CELLS | PTEN LOSS | PIK3CA MUTATIONS | ENHANCED SENSITIVITY | EVEROLIMUS | MTOR | ONCOLOGY | PRECLINICAL MODELS | SIGNALING PATHWAY | RESISTANCE | INHIBITOR | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Neoplasm Metastasis | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Female | Mutation | Immunohistochemistry | Antimitotic agents | Cancer patients | Analysis | Estrogen | Clinical trials | Product development | Metastasis | Antineoplastic agents | Formaldehyde
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 5/2018, Volume 101, Issue 1, pp. 177 - 185
CALGB 31102 was a limited institution Phase I trial to establish a maximum tolerated dose of accelerated hypofractionated radiotherapy given concurrent with...
clinical trial | chemoradiotherapy | hypofractionation | novel radiotherapy
clinical trial | chemoradiotherapy | hypofractionation | novel radiotherapy
Journal Article
Journal of Cancer Education, ISSN 0885-8195, 02/2019, Volume 34, Issue 1, pp. 50 - 55
As the population of patients with cancer and survivors grows, physician knowledge of oncology clinical care and research is increasingly important. Despite...
Interprofessional | Cancer research | Undergraduate medical education | Radiation oncology | Multidisciplinary | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | ONCOLOGY | STATISTICS | KNOWLEDGE | EDUCATION, SCIENTIFIC DISCIPLINES | Medical students | Curricula | Education | Analysis | Methods | Radiation
Interprofessional | Cancer research | Undergraduate medical education | Radiation oncology | Multidisciplinary | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | ONCOLOGY | STATISTICS | KNOWLEDGE | EDUCATION, SCIENTIFIC DISCIPLINES | Medical students | Curricula | Education | Analysis | Methods | Radiation
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e18193 - e18193
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 4503 - 4503
Journal Article
The Oncologist, ISSN 1083-7159, 11/2019, Volume 24, Issue 11, pp. 1497 - 1501
Cabozantinib treatment prolonged progression‐free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced...
Brief Communications
Brief Communications
Journal Article
BJU international, ISSN 1464-4096, 4/2018, Volume 121, Issue 4, pp. 534 - 539
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 22, pp. 2602 - 2609
Purpose To investigate whether anti-vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to...
EFFICACY | ONCOLOGY | TAMOXIFEN | DOUBLE-BLIND | ESTROGEN | FACTOR EXPRESSION | ADJUVANT BEVACIZUMAB | COMBINATION | PLUS BEVACIZUMAB | ENDOTHELIAL GROWTH-FACTOR | FIRST-LINE THERAPY | Triazoles - administration & dosage | Bevacizumab - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Nitriles - administration & dosage | Disease-Free Survival | Angiogenesis Inhibitors - administration & dosage | Aged, 80 and over | Postmenopause | Adult | Female | Aged | Nitriles - therapeutic use | Triazoles - therapeutic use | Index Medicus | ORIGINAL REPORTS | Bc7
EFFICACY | ONCOLOGY | TAMOXIFEN | DOUBLE-BLIND | ESTROGEN | FACTOR EXPRESSION | ADJUVANT BEVACIZUMAB | COMBINATION | PLUS BEVACIZUMAB | ENDOTHELIAL GROWTH-FACTOR | FIRST-LINE THERAPY | Triazoles - administration & dosage | Bevacizumab - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Nitriles - administration & dosage | Disease-Free Survival | Angiogenesis Inhibitors - administration & dosage | Aged, 80 and over | Postmenopause | Adult | Female | Aged | Nitriles - therapeutic use | Triazoles - therapeutic use | Index Medicus | ORIGINAL REPORTS | Bc7
Journal Article
Journal of Cancer Education, ISSN 0885-8195, 6/2018, Volume 33, Issue 3, pp. 622 - 626
Oncologists must have a strong understanding of collaborating specialties in order to deliver optimal cancer care. The objective of this study was to quantify...
Biomedicine | Graduate Medical Education | Radiation oncology | Surgery | Patient care team | Hospice care | Cancer Research | Medical oncology | Pharmacology/Toxicology | Communication | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | ONCOLOGY | EDUCATION, SCIENTIFIC DISCIPLINES | CARE | Surveys | Training | Medical colleges | Teachers | Education | College graduates | Radiation | Palliative treatment | Public opinion | Oncology | Teaching methods | Interdisciplinary aspects
Biomedicine | Graduate Medical Education | Radiation oncology | Surgery | Patient care team | Hospice care | Cancer Research | Medical oncology | Pharmacology/Toxicology | Communication | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | ONCOLOGY | EDUCATION, SCIENTIFIC DISCIPLINES | CARE | Surveys | Training | Medical colleges | Teachers | Education | College graduates | Radiation | Palliative treatment | Public opinion | Oncology | Teaching methods | Interdisciplinary aspects
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2018, Volume 103, p. 287
Journal Article